Debate 2: The preferred second line therapy in patients with T2D is … ?

In a debate moderated by Professor Thomas, Professor Inzucchi takes the position that an SGLT2 inhibitor should be the preferred second-line therapy in patients with T2D. Professor Giorgino takes the opposing position that GLP-1 RAs should be the preferred second-line therapy in patients with T2D.